Company / Operating Cash Flow
Altimmune, Inc. Operating Cash Flow History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$67.5M
FY2025
5-year range
-$78.2M / -$34.3M
FY2021-FY2025
Trend
+10.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$78M in FY2022 to -$6M in FY2017.
Based on SEC 10-K filings.
-$68M in FY2025.
Declined from -$63M to -$68M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 10.9% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$67.5M | +10.9% |
| FY2024 | -$75.8M | -21.1% |
| FY2023 | -$62.6M | +20.0% |
| FY2022 | -$78.2M | -128.1% |
| FY2021 | -$34.3M | -257.3% |
| FY2020 | -$9.6M | -2.3% |
| FY2019 | -$9.4M | +53.6% |
| FY2018 | -$20.2M | -218.2% |
| FY2017 | -$6.4M | +57.3% |
| FY2011 | -$14.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026